Peptides, GLP-1s & Dementia

About this video

Despite its title, the pulled transcript for this office-hours episode covers a different question: shingles reactivation risk in people with type 2 diabetes who use GLP-1 medicines. Seeds argues clinicians should keep baseline risk in perspective, claiming reactivation already occurs at a meaningful rate in diabetic populations and that, in the data he cites, adding a GLP-1 is associated with a further relative increase, with cases skewing toward younger women with poorly controlled glucose. He frames this as a phenotyping issue — identifying which patients carry upstream drivers of vulnerability — rather than a reason for alarm. The transcript ends mid-discussion, so the full reasoning and any conclusions about dementia are not present in the pulled captions.

Key takeaways

• Seeds argues medication risk should always be weighed against the baseline risk of the underlying condition
• He identifies poorly controlled glucose as a key part of the patient phenotype he worries about
• He presents relative risk increases in absolute, per-population terms to keep the concern proportionate
• He treats viral reactivation as a signal to phenotype the patient, not just to blame the drug

Episode details: published June 8, 2026 · 570 views · 2:54 long. Summary written by Self Growth Videos from the episode itself. The peptide and cellular-medicine concepts described are Dr. William Seeds’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: the SSRP Institute sells clinician certification in peptide therapy.

← Previous: BPC The Healing Peptide · Next: Don’t Buy Peptides Online #health #peptides →

All Dr. William Seeds videos · Dr. William Seeds profile · SSRP Institute (official site)